22.418 articles found

Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW.

J Pharmacol Exp Ther · 2007-07-27

DOI: 10.1124/jpet.107.126219PMID: 17660384

3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER.

MC KITTRICK BRIAN, CHAN TIN-YAU, FISCHMANN THIERRY O, MC COY MARK A, PRONGAY ANDREW, PU HAIYAN, WANG LI.

· 2007-07-25

NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME

SOKOLOFF PIERRE, IMBERT THIERRY, VERGNES LAURENT, CUISIAT FLORENCE.

· 2007-07-20

Occupational therapy for patients with Parkinson's disease.

Dixon L, Duncan D, Johnson P, Kirkby L, O'Connell H, Taylor H, Deane KH.

Cochrane Database Syst Rev · 2007-07-18

DOI: 10.1002/14651858.cd002813.pub2PMID: 17636709

Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Tansey MG, McCoy MK, Frank-Cannon TC.

Exp Neurol · 2007-07-17

DOI: 10.1016/j.expneurol.2007.07.004PMID: 17720159

L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.

Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A.

J Chem Neuroanat · 2007-07-17

DOI: 10.1016/j.jchemneu.2007.06.004PMID: 17706922

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.

Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, Papa SM.

J Pharmacol Exp Ther · 2007-07-13

DOI: 10.1124/jpet.107.125666PMID: 17630359

From a Parkinson's disease expert: Rasagiline and the future of therapy.

Lakhan SE.

Mol Neurodegener · 2007-07-06

DOI: 10.1186/1750-1326-2-13PMID: 17617893

PHARMACEUTICAL COMPOSITION COMPRISING SUBSTITUTED BENZENE ANALOG COMPOUND WITH NEUROPROTECTIVE ACTIVITIES FOR THE TREATMENT OF NEUROLOGICAL BRAIN DISEASE COMPRISING PARKINSON'S DISEASE AND METHOD FOR TREATING BRAIN DISORDER USING THE COMPOUNMD

PARK CHEOL HYOUNG, LEE JI WON, CHUNG JIN YONG, RYU CHOON HO, YOON YEO JIN, JI MI KYUNG, MIN HYE KYUNG.

· 2007-07-04

Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine.

Davidson C, Chen Q, Zhang X, Xiong X, Lazarus C, Lee TH, Ellinwood EH.

Eur J Pharmacol · 2007-07-04

DOI: 10.1016/j.ejphar.2007.06.046PMID: 17651730

Gene transfer therapy for neurodegenerative disorders.

Feigin A, Eidelberg D.

Mov Disord · 2007-07-01

DOI: 10.1002/mds.21423PMID: 17393533

Levodopa-induced dyskinesias.

Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG.

Mov Disord · 2007-07-01

DOI: 10.1002/mds.21475PMID: 17427940